Medigene spin-off Immunocore has formed its first major collaboration by partnering with Roche’s Genentech for the discovery and development of multiple novel cancer targets using its ImmTAC® (immune mobilising mTCR against cancer) technology platform. For each programme, Immunocore will receive an initiation fee of between US$10 M and US$20 M and could receive more than US$300 M in milestones plus tiered royalties. The ImmTAC platform involves engineering high-affinity TCRs (T-cell receptors) and linking them to anti-CD3 antibody fragments that activate the immune system to form bispecific therapeutics that are able to target intracellular cancer antigens.